Plain-English translation of NCT07193953 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing intravenous immunoglobulin (IVIG), an immune-boosting medication, combined with focused ultrasound technology to deliver it directly to the motor cortex in people with ALS. The study uses a specialized ultrasound helmet to temporarily open the blood-brain barrier—a natural protective layer around the brain—so that more of the medication can reach the nerve cells affected by ALS. Researchers hope this targeted delivery approach may help reduce brain inflammation and slow disease progression.
Standard treatments for ALS have limited ability to reach the brain tissue where nerve damage occurs. This trial is exploring whether using ultrasound to temporarily open the brain's protective barrier could allow the medication to work more effectively at the source of the problem.
You would receive the medication intravenously (through an IV) twice over two weeks. During the second dose, you would undergo a focused ultrasound procedure using a specialized helmet to open the blood-brain barrier and enhance medication delivery to your motor cortex. You would need to undergo an MRI scan, have blood work done, and attend follow-up visits over 24 weeks to monitor your safety and how your body responds to the treatment.
AI-generated summary from trial data · Aug 7, 2026 · Not medical advice
Canada